Cargando…
Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe
BACKGROUND AND OBJECTIVE: Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911507/ https://www.ncbi.nlm.nih.gov/pubmed/36630078 http://dx.doi.org/10.1007/s40271-022-00614-7 |
_version_ | 1784885003700666368 |
---|---|
author | Willems, Damon Hinzpeter, Eva-Lotta Van der Zee, Hessel H. Sayed, Christopher J. Ingram, John R. Beaudart, Charlotte Evers, Silvia M. A. A. Hiligsmann, Mickael |
author_facet | Willems, Damon Hinzpeter, Eva-Lotta Van der Zee, Hessel H. Sayed, Christopher J. Ingram, John R. Beaudart, Charlotte Evers, Silvia M. A. A. Hiligsmann, Mickael |
author_sort | Willems, Damon |
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making have scarcely been investigated. This study aimed to reveal which treatment attributes adult patients with HS in Europe consider most important in treatment decision-making. METHODS: A discrete choice experiment was conducted with adult patients with hidradenitis suppurativa in Europe to reveal which treatment attributes are most important when making treatment decisions. Participants were presented with 15 sets of two treatment options and asked for each to choose the treatment they preferred. The treatments were characterized by six attributes informed by a prior literature review and qualitative research: effectiveness, pain reduction, duration of treatment benefit, risk of mild adverse event, risk of serious infection, and mode of administration. A random parameter logit model was used to estimate patients’ preferences with additional subgroup and latent class models used to explore any differences in preferences across patient groups. RESULTS: Two hundred and nineteen adult patients with hidradenitis suppurativa were included in the analysis (90% women, mean age 38 years). For all six treatment attributes, significant differences were observed between levels. Given the range of levels of each attribute, the most important treatment attributes were effectiveness (47.9%), followed by pain reduction (17.3%), annual risk of a mild adverse event (14.4%), annual risk of a serious infection (10.3%), mode of administration (5.3%), and duration of treatment benefit (4.8%). Higher levels of effectiveness, namely a 75% or 100% reduction in the abscess and inflammatory nodule count, were preferred over levels of effectiveness primarily investigated in randomized clinical trials of hidradenitis suppurativa (a 50% reduction). Results were largely consistent across subgroups and three latent class groups were identified. CONCLUSIONS: This study revealed the most important treatment characteristics for patients with hidradenitis suppurativa that can help inform joint patient-physician decision making in the management of hidradenitis suppurativa. Designing future hidradenitis suppurativa treatments according to stated preferences, namely, to offer higher levels of effectiveness and pain improvement without higher risks of adverse events, may increase patients’ treatment concordance and lead to improved disease management outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-022-00614-7. |
format | Online Article Text |
id | pubmed-9911507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-99115072023-02-11 Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe Willems, Damon Hinzpeter, Eva-Lotta Van der Zee, Hessel H. Sayed, Christopher J. Ingram, John R. Beaudart, Charlotte Evers, Silvia M. A. A. Hiligsmann, Mickael Patient Original Research Article BACKGROUND AND OBJECTIVE: Hidradenitis suppurativa is a chronic inflammatory skin disease that can lead to a substantial reduction in quality of life. Recent studies revealed high levels of unmet care needs of patients with hidradenitis suppurativa, but their preferences in treatment decision making have scarcely been investigated. This study aimed to reveal which treatment attributes adult patients with HS in Europe consider most important in treatment decision-making. METHODS: A discrete choice experiment was conducted with adult patients with hidradenitis suppurativa in Europe to reveal which treatment attributes are most important when making treatment decisions. Participants were presented with 15 sets of two treatment options and asked for each to choose the treatment they preferred. The treatments were characterized by six attributes informed by a prior literature review and qualitative research: effectiveness, pain reduction, duration of treatment benefit, risk of mild adverse event, risk of serious infection, and mode of administration. A random parameter logit model was used to estimate patients’ preferences with additional subgroup and latent class models used to explore any differences in preferences across patient groups. RESULTS: Two hundred and nineteen adult patients with hidradenitis suppurativa were included in the analysis (90% women, mean age 38 years). For all six treatment attributes, significant differences were observed between levels. Given the range of levels of each attribute, the most important treatment attributes were effectiveness (47.9%), followed by pain reduction (17.3%), annual risk of a mild adverse event (14.4%), annual risk of a serious infection (10.3%), mode of administration (5.3%), and duration of treatment benefit (4.8%). Higher levels of effectiveness, namely a 75% or 100% reduction in the abscess and inflammatory nodule count, were preferred over levels of effectiveness primarily investigated in randomized clinical trials of hidradenitis suppurativa (a 50% reduction). Results were largely consistent across subgroups and three latent class groups were identified. CONCLUSIONS: This study revealed the most important treatment characteristics for patients with hidradenitis suppurativa that can help inform joint patient-physician decision making in the management of hidradenitis suppurativa. Designing future hidradenitis suppurativa treatments according to stated preferences, namely, to offer higher levels of effectiveness and pain improvement without higher risks of adverse events, may increase patients’ treatment concordance and lead to improved disease management outcomes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40271-022-00614-7. Springer International Publishing 2023-01-11 2023 /pmc/articles/PMC9911507/ /pubmed/36630078 http://dx.doi.org/10.1007/s40271-022-00614-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Willems, Damon Hinzpeter, Eva-Lotta Van der Zee, Hessel H. Sayed, Christopher J. Ingram, John R. Beaudart, Charlotte Evers, Silvia M. A. A. Hiligsmann, Mickael Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title | Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title_full | Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title_fullStr | Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title_full_unstemmed | Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title_short | Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe |
title_sort | patient preferences in the management of hidradenitis suppurativa: results of a multinational discrete choice experiment in europe |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911507/ https://www.ncbi.nlm.nih.gov/pubmed/36630078 http://dx.doi.org/10.1007/s40271-022-00614-7 |
work_keys_str_mv | AT willemsdamon patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT hinzpeterevalotta patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT vanderzeehesselh patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT sayedchristopherj patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT ingramjohnr patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT beaudartcharlotte patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT everssilviamaa patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope AT hiligsmannmickael patientpreferencesinthemanagementofhidradenitissuppurativaresultsofamultinationaldiscretechoiceexperimentineurope |